[go: up one dir, main page]

MX2008001645A - Composiciones de fexofendina en suspension farmaceutica oral. - Google Patents

Composiciones de fexofendina en suspension farmaceutica oral.

Info

Publication number
MX2008001645A
MX2008001645A MX2008001645A MX2008001645A MX2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A
Authority
MX
Mexico
Prior art keywords
fexofenadine
pharmaceutical suspension
oral pharmaceutical
suspension compositions
oral
Prior art date
Application number
MX2008001645A
Other languages
English (en)
Inventor
Himadrisen
Surya Kumar Jayanthi
Nitin S Deshmukh
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2008001645A publication Critical patent/MX2008001645A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion de fexofenadina en suspension farmaceutia oral. La fexofenadina es una mezcla de fexofenadina compactada y fexofenadina simple en una relacion de 0.01: 0.99 a 0.99 a 0.01 con un tamano de particula medio de las particulas de fexofenadina en el intervalo de 10( a 250(. Una composicion de fexofenadina en suspension farmaceutica oral, que es bioequivalente a una forma farmaceutica en tableta de fexofenadina comercializada con el nombre comercial Allegra(r). La bioequivalencia entre una formulacion en suspension y la formulacion comercial en forma de tableta de fexofenadina, es decir, `Allegra(r)??, se logra mediante el uso de una mezcla de fexofenadina compactada.
MX2008001645A 2005-08-05 2006-08-03 Composiciones de fexofendina en suspension farmaceutica oral. MX2008001645A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN703KO2005 2005-08-05
PCT/IN2006/000277 WO2007017905A1 (en) 2005-08-05 2006-08-03 Oral pharmaceutical suspension compositions of fexofenadine

Publications (1)

Publication Number Publication Date
MX2008001645A true MX2008001645A (es) 2008-04-07

Family

ID=37529426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001645A MX2008001645A (es) 2005-08-05 2006-08-03 Composiciones de fexofendina en suspension farmaceutica oral.

Country Status (5)

Country Link
US (1) US20080274196A1 (es)
JP (1) JP5133244B2 (es)
BR (1) BRPI0614231A2 (es)
MX (1) MX2008001645A (es)
WO (1) WO2007017905A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
AR094761A1 (es) * 2013-02-14 2015-08-26 Sanofi Sa Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma
PL2956011T3 (pl) * 2013-02-14 2018-09-28 Sanofi Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania
JP6410814B2 (ja) * 2013-07-01 2018-10-24 アベンティスユービー・エルエルシー フェキソフェナジンを含む経口投与用液体医薬組成物
CN107536804A (zh) * 2016-06-28 2018-01-05 浙江普利药业有限公司 盐酸非索非那定干混悬剂及其制备方法
WO2019038584A1 (en) * 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
JP7546138B2 (ja) * 2021-12-21 2024-09-05 上海奥全生物医葯科技有限公司 固形剤形を水に分散させて懸濁液を形成する方法、懸濁液および固体剤形を投与する方法
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
CA3260005A1 (en) * 2023-01-20 2024-07-25 Opella Healthcare Group Sas PARABEN-FREE FEXOFENADINE FORMULATIONS
CN118286163B (zh) * 2024-04-03 2025-07-15 桂林华信制药有限公司 一种盐酸非索非那定干混悬剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
ATE444731T1 (de) * 2003-01-30 2009-10-15 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs

Also Published As

Publication number Publication date
WO2007017905A1 (en) 2007-02-15
US20080274196A1 (en) 2008-11-06
BRPI0614231A2 (pt) 2012-12-11
JP5133244B2 (ja) 2013-01-30
JP2009503058A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
MX2010008234A (es) Nueva dosificacion y formulacion.
DE60231298D1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
MY177027A (en) Novel dosage and formulation
EA200600479A1 (ru) Фармацевтический состав, включающий соединения лантана
UA116334C2 (uk) Тверді форми дозування бендамустину
BRPI0413277A (pt) composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
CA2535013A1 (en) Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ATE533476T1 (de) Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE488225T1 (de) Kaubare, lutschbare und verschluckbare tablette mit einer calciumhaltigen verbindung als wirkstoff
MY177591A (en) Nk1 receptor antagonist composition
MY160417A (en) Amino-acid-containing medicinal granular preparation highly easy to take
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
PL382307A1 (pl) Sposób przygotowania farmaceutycznej kompozycji w postaci szybko dyspersyjnej dawki i stała, doustna, szybko dyspersyjna postać dawki
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
WO2006096194A8 (en) Drinkable immediate release tablet made with direct compression of memantine or neramexane